Although the meta-analysis of placebo-controlled clinical trials suggested that benefit for MACEs with SGLT-2 inhibitors or GLP-1RAs did not differ by history of HF,4 we observed larger benefit for the modified MACE outcome with empagliflozin relative to liraglutide in patients with HF history than in those without it. This evidence concerns the gene SLC5A2 and hydrops fetalis.